Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of lunsekimig in adults with chronic rhinosinusitis with nasal polyps
2024-515912-27-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Dec 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of lunsekimig in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Sanofi. Primary endpoint: Incidence of participants with treatment-emergent adverse events including adverse events of special interest and serious adverse events. Planned start Dec 2025; status: authorised.
02
Drugs
lunsekimig
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2024-515912-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515912-27-00.